Skip to main content

Table 2 Effect of bitter melon and glibenclamide on clinical/metabolic variables of study groups

From: Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients

Variables Baseline Endpoint (week 10)
FPG (mg/dl)
Bitter melon 2 g/day (Group I) 146±13.40 133.70±11.50*
Bitter melon 4 g/day (Group II) 141.60±15.20 126.40±11.90*
Glibenclamide 5 mg/day (Group III) 143.50±18.40 117±10.30¤
2 h post OGTT plasma glucose (mg/dl)
Bitter melon 2 g/day (Group I) 241.30±15.60 235±19.50
Bitter melon 4 g/day (Group II) 247±21.90 240.70±25.10
Glibenclamide 5 mg/day (Group III) 255.60±26.30 229.40±20.80*
T C (mg/dl)
Bitter melon 2 g/day (Group I) 218.25±10.70 214.50±14.50
Bitter melon 4 g/day (Group II) 227.10±15.50 221±11.60
Glibenclamide 5 mg/day (Group III) 220.50±11.10 222±10.80
LDL-c (mg/dl)
Bitter melon 2 g/day (Group I) 149.70±18.20 146.50±11.50
Bitter melon 4 g/day (Group II) 154±15.50 148.90±16.40
Glibenclamide 5 mg/day (Group III) 146.80±10.30 148.50±12.35
HDL-c (mg/dl)
Bitter melon 2 g/day (Group I) 48.15±4.90 50±3.50
Bitter melon 4 g/day (Group II) 47.60±5.70 51.20±4.20
Glibenclamide 5 mg/day (Group III) 48.10±5.50 45±4.90
T G (mg/dl)
Bitter melon 2 g/day (Group I) 163.20±17.50 159.80±16.70
Bitter melon 4 g/day (Group II) 168±13.40 154.20±11.80*
Glibenclamide 5 mg/day (Group III) 165.50±20.50 172.90±18.40
T C/HDL-c ratio
Bitter melon 2 g/day (Group I) 4.53±1.10 4.29±1.20
Bitter melon 4 g/day (Group II) 4.77±1.60 4.31±1.35
Glibenclamide 5 mg/day (Group III) 4.58±1.15 4.93±1.50
LDL-c/HDL-c ratio
Bitter melon 2 g/day (Group I) 3.10±1.35 2.93±1.10
Bitter melon 4 g/day (Group II) 3.23±1.52 2.89±1.31
Glibenclamide 5 mg/day (Group III) 3±1.47 3.30±1.20
SBP (mmHg)
Bitter melon 2 g/day (Group I) 139±8.10 135.50±11.90
Bitter melon 4 g/day (Group II) 144.80±23.70 133.10±14.30*
Glibenclamide 5 mg/day (Group III 136.20±12.24 135.50±10.50
Weight (Kg)
Bitter melon 2 g/day (Group I) 69.50±10.70 67.65±11.32
Bitter melon 4 g/day (Group II) 73.90±12.20 70.80±10.50
Glibenclamide 5 mg/day (Group III 68.40±8.30 70±11.90
  1. *p≤0.05 compared to baseline; ¤p≤0.01 compared to baseline; p≤0.05 compared to group III at week 10.